Table 3.

Ongoing studies using nivolumab in advanced melanoma

Study population	Phase	Drugs	Primary outcomes	ClinicalTrials.gov identifier
BRAF-mutated melanoma
Sequential checkpoint blockade	3	Dab + Tram → Nivo + Ipi vs Nivo + Ipi → Dab + Tram	Overall survival: 2 years	NCT02224781
CheckMate 064	2	Nivo → Ipi vs Ipi → Nivo	Treatment-related Gr 3–5 AEs	NCT01783938
Neoadjuvant checkpoint blockade	2	Nivo + Ipi → Nivo vs Nivo alone	Pathologic response and pCR	NCT02519322
Brain metastases
ABC	2	Nivo + Ipi → Nivo vs Nivo alone	Intracranial response rate	NCT02374242
CheckMate 204	2	Nivo + Ipi → Nivo	Clinical benefit rate	NCT02320058
Rare melanoma subtypes
Metastatic uveal melanoma	2	Nivo + Ipi → Nivo	Overall response rate	NCT01585194
KIT mutation	2	Sunitinib + Nivo	Objective response rate	NCT02400385
Correlative analyses
Pharmacodynamic biomarker analysis	1	Nivo + Ipi vs Nivo alone	Immunomodulatory effects	NCT01621490
Relationship between tumor mutation burden and neoantigen load	2	Nivo + Ipi vs Nivo alone	Response rate	NCT02553642

Abbreviations: Dab, dabrafenib; Tram, trametinib; Nivo, nivolumab; Ipi, ipilimumab; Gr, grade; AEs, adverse events; pCR, pathologic complete response; ABC, anti-PD-1 brain collaboration; PD-1, programmed death-1.